For the quarter ending 2025-09-30, CTNM had $21,849K increase in cash & cash equivalents over the period. -$12,295K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -12,792 | -32,030 |
| Depreciation and amortization | 81 | 157 |
| Non-cash operating lease expense | 233 | 460 |
| Stock-based compensation | 2,569 | 4,987 |
| Loss on disposal of property and equipment | - | -67 |
| Accretion of premiums/discounts on marketable securities, net | -4 | 692 |
| Change in fair value of warrant liability | 0 | 0 |
| Loss on disposal of property and equipment | -67 | - |
| Gain on sale of equipment | 0 | - |
| Gain on marketable securities | 0 | 6 |
| Prepaid expenses and other current assets | 1,165 | -273 |
| Other long-term assets | 0 | 6 |
| Accounts payable | -1,221 | 190 |
| Accrued expenses | 351 | -2,964 |
| Operating lease liabilities | -257 | -509 |
| Net cash used in operating activities | -12,197 | -30,073 |
| Purchase of property and equipment | 98 | 91 |
| Proceeds from sale of equipment | 0 | - |
| Purchases of marketable securities | 18,641 | 59,128 |
| Sales and maturities of marketable securities | 33,680 | 88,018 |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | - | 0 |
| Net cash provided by (used in) investing activities | 14,941 | 28,799 |
| Payments of deferred offering costs | 80 | 176 |
| Proceeds from issuance of common stock-IPO | 0 | - |
| Proceeds from issuance of common stock-At The Market Offering | 19,012 | - |
| Proceeds from exercise of stock options | 173 | 24 |
| Proceeds from employee stock purchase plan | 0 | 267 |
| Net cash provided by financing activities | 19,105 | 115 |
| Net increase in cash and cash equivalents | 21,849 | -1,159 |
| Cash and cash equivalents at beginning of period | 21,943 | - |
| Cash and cash equivalents at end of period | 42,633 | - |
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)